E&L – uventia https://www.uventia.com We make the event you need Mon, 01 Apr 2024 14:00:27 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.3 184090477 Tobias Weimer https://www.uventia.com/speaker/tobias-weimer/ Wed, 21 Feb 2024 14:54:55 +0000 https://www.uventia.com/?post_type=speaker&p=8755
Tobias Weimer

Tobias Weimer

Product Specialist LC-MS

Agilent

Tobias Weimer hat in Marburg an der Philipps Universität Chemie studiert. Seine Leidenschaft für die analytische Chemie und Chromatographie wurde bereits in der Oberschule geweckt und im Studium vertieft mit einer gezielten Ausrichtung auf analytische Trenntechniken. Über die Flüssigkeitschromatographie im Bereich LC Säulen führte Ihn sein Weg zu LC-Systemen.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 2: MARCH 8th, 2024

SESSION: Perfecting Extractable and Leachable Testing – Explore multiple analytical approaches to accurately identify and quantify extractable and leachable compounds

◆  Agilent comprehensive portfolio to mitigate risk of E&L.

◆  Analytical Workflow strategies & Solution:

  • Scouting approach using modern molecular spectroscopy solution.
  • Identification & quantitation of E&L for volatile/ Semi-volatile Impurities using GCMS solution.
  • Streamlining Elemental Impurities, Extractables and Leachable Workflows Flow with Agilent Time Trap Analytical Solution.
]]>
8755
J. Susanne Becker https://www.uventia.com/speaker/j-susanne-becker/ Mon, 05 Feb 2024 11:12:11 +0000 https://www.uventia.com/?post_type=speaker&p=8736
J. Susanne Becker

J. Susanne Becker

Head of Extractables and Leachables Labs

Intertek

J. Susanne Becker did her Ph.D. at the University of Konstanz in Analytical Chemistry in the field of Proteomics and Organic Mass Spectrometry. After several years’ experience in the pharmaceutical industry at Aeropharm and Baxter as Analytical Expert and Project Manager, she joined Intertek (Schweiz) AG in April 2016, where she is working as Project leader in E&L and since 2021 as Head of Extractables and Leachables Labs.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 1: MARCH 7th, 2024

SESSION: From Extractables Study to Leachables Study – from screening methods to validated target methods for Stability Testing in E&L

◆  Set of Extractables Study under realistic worst-case conditions.

◆  Leachables Simulation Study using drug substance/product solution.

◆  Selections of target compounds, method development and validation according to ICH.

◆  Case studies showing problems and possible solutions.

]]>
8736
Will Parker https://www.uventia.com/speaker/will-parker/ Wed, 20 Dec 2023 14:52:11 +0000 https://www.uventia.com/?post_type=speaker&p=8370
Will Parker

Will Parker

E&L Technology Manager

WestPharma

Will Parker earned a B.S. in chemistry in 2004 from Penn State Erie where he will soon be serving on a School of Science alumni advisory board and will be earning a master’s degree in data analytics from Penn State in May 2024. Will has over 18 years of analytical chemistry professional experience with 13 of them in extractables and leachables labs as both a lab scientist and manager. He has spent the past nearly 8 years in lab management roles, mostly in E&L, with his current role as the E&L technology manager at West where he assists Services and Solutions in meeting industry expectations and our clients’ needs. Will has designed and executed hundreds of various E&L studies comprising the breadth of the field including studies of drug product packaging, manufacturing in-process contact materials, single-use systems, and medical devices.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 2: MARCH 8th, 2024

SESSION: Elastomer closures materials (TBC)

◆  Composition of elastomers used for pharmaceutical applications.

◆  Material composition and extractables.

◆  How to minimize extractables/leachables from elastomeric closures.

]]>
8370
Ana Kuschel https://www.uventia.com/speaker/ana-kuschel/ Wed, 20 Dec 2023 14:47:09 +0000 https://www.uventia.com/?post_type=speaker&p=8365
Ana Kuschel

Ana Kuschel

Principal Scientific Affairs

WestPharma

Ana Kuschel as Principal Scientific Affairs Europe is providing technical support relating to West’s packaging components and delivery systems for injectable drugs and healthcare products. As well as bridging scientific information through industry outreach. This is complementing her previous role as Manager Material Development, where she worked on both existing and new rubber formulations.
Ana holds a PhD in macromolecular chemistry and is an active member of the ISO TC 76 and PDA Packaging Science groups.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 2: MARCH 8th, 2024

SESSION: Elastomer closures materials (TBC)

◆  Composition of elastomers used for pharmaceutical applications.

◆  Material composition and extractables.

◆  How to minimize extractables/leachables from elastomeric closures.

]]>
8365
Armin Hauk https://www.uventia.com/speaker/armin-hauk/ Thu, 07 Dec 2023 12:03:38 +0000 https://www.uventia.com/?post_type=speaker&p=7616
Armin Hauk

Armin Hauk

Principal Scientist

Sartorius-Stedim-Biotech-GmbH

Armin Hauk has a position as Principal Scientist at Sartorius Stedim Biotech GmbH since 2016. Before that he was over 20 years active as head of laboratories for organic trace-analysis, GLP & GMP analytics in Ciba-Geigy, Novartis, and Ciba Specialty Chemicals. For Intertek, Switzerland he worked as consultant and Qualified Person (QP). Armin is a lecturer and trainer in E&L at conferences and seminars and is a member of various industry consortia (BPSA, BPOG, DECHEMA, and MIT BioMan). He is chairperson of the Pharmacopeia expert group 16 in the European Directorate for Quality of Medicine (EDQM).

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 1: MARCH 7th, 2024

SESSION: Extractables and leachables from single-use systems and their assessment in advanced therapy medicinal product (ATMP) production

◆  E&L safety assessment in cell and gene therapies (CGT) is challenging.

◆  While suitable extractables data are available, exposure estimations to patients and the ex vivo manipulated biological material need to be improved by exposure modelling..

◆  Additionally, data for toxicological relevant end points for the ex vivo manipulated cells are required.

◆  It will be shown that morphological profiling with a cell painting assays (CPA) using human cells allows to identify potential detrimental effects relevant for E&L safety assessments.

]]>
7616
Katherine Lovejoy https://www.uventia.com/speaker/katherine-lovejoy/ Thu, 16 Nov 2023 20:12:28 +0000 https://www.uventia.com/?post_type=speaker&p=7188
Katherine Lovejoy

Katherine Lovejoy

Application Chemist

Thermo-Fisher-Scientific

Katherine Lovejoy is an Application Chemist at the Thermo Fisher Scientific production site for HPLC and for the charged aerosol detector. She has 7 years of experience in that role and enjoys helping others get the best possible CAD results. She earned a PhD in Inorganic Chemistry from the Massachusetts Institute of Technology and has a h-index of 15. Her experience also includes time as a chemist reviewer at the FDA and a scientist at Los Alamos National Laboratory.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 1: MARCH 7th, 2024

SESSION: Implementation of a non-volatility test before quantitating E&L unknowns with a charged aerosol detector

◆  HPLC with 3 orthogonal detectors allows quantitation of unknowns by charged aerosol detectorand identification by easy-to-use low resolution MS

◆  Classification of unknowns as non-volatile or semi-volatile in the CAD reduces the uncertainty factor and improves quantification by surrogate standard.

◆  When using an inverse gradient, improved mixing with an inline capillary mixer after the merge point of the analytical and inverse gradients reduces inter-compound %RSD

]]>
7188
Jason Creasey https://www.uventia.com/speaker/jason-creasey/ Fri, 03 Nov 2023 17:24:06 +0000 https://www.uventia.com/?post_type=speaker&p=6502
Jason Creasey

Jason Creasey

Managing Director

Maven-E&L-Ltd

Jason Creasey is a graduate analytical chemist. In 2019, he established Maven E&L Ltd, as its Manging Director and Principal Consultant. Maven E&L was setup to provide advice to clients working in the pharmaceutical industry on all aspects relating to the topic of extractables and leachables (E&L) and the risks that leachables pose to the quality and safety of drug products. Prior to this, he worked for GSK where he was the director of their R&D E&L Team.

He has worked in the topic area of E&L since the mid 1990’s on a wide range of modalities and dose forms seeing this area expand and grow in significance for the pharmaceutical and medical device industries. In addition to running his consultancy, he is a scientific advisor to the ELSIE consortium. Since setting up Maven E&L; he continues to present, discuss, and write about E&L. He now publishes a regular E&L blog through LinkedIn and his Website (www.MavenEandL.com), for the exchange of ideas and discussion.

As well as supporting client projects, among recent E&L activity, he is presenting and commenting on risk- based approaches to E&L requirements within the pharmaceutical industry that he hopes will form part of an ICH guidance in the not-too-distant future and has helped ELSIE publish and discuss their whitepapers linked to Concepts in Leachable Risk Management and develop their database further.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 2: MARCH 8th, 2024

SESSION: Leachable risk assessment approaches: a comparison of USP , biophorum, and other methods for assessing leachable risk in biopharmaceutical manufacturing systems

◆  There is no agreed format for leachable risk assessment.

◆  Both USP and Biophorum have published guidance.

◆  Presented is an alternative approach that might be considered, covering both severity and probability of leachable risk.

]]>
6502
Divya Regulagedda https://www.uventia.com/speaker/divya-regulagedda/ Mon, 30 Oct 2023 17:05:46 +0000 https://www.uventia.com/?post_type=speaker&p=6488
Divya Regulagedda

Divya Regulagedda

Manager (Global SME)

Chemo

Divya Regulagedda is analytical person from technical perspective and have experience in the field of E & L for 11+ years. She has hands on experience with LC-MS/MS, LC-QTOF, GC-MS/MS, ICP-MS and IC.
Previously, she worked with a CRO and was responsible for the work of E &L.

Currently, she is responsible for the E & L work in Insud Pharma for Pharmaceutical products and medical devices.
Also, she has experience with risk assessments and toxicological evaluations.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 2: MARCH 8th, 2024

SESSION: E&L testing for medical devices

◆  Chemical characterisation of medical device materials and ISO 10993-18.

◆  Evaluation of biocompatibility and toxicological risk.

◆  The verification of analytical methods.

]]>
6488
Jianwei Li https://www.uventia.com/speaker/jianwei-li/ Mon, 30 Oct 2023 15:15:27 +0000 https://www.uventia.com/?post_type=speaker&p=6478
Jianwei Li

Dr. Jianwei Li

Principal E&L and Chemical Characterization Consultant and Technical Writer

Chemical Characterization Solutions LLC
The United States

Dr. Jianwei Li is currently the principal E&L and chemical characterization consultant, and chemistry writer at Chemical Characterization Solutions LLC. He worked at Medtronic for nearly 17 years as a technical fellow and subject matter expert in the chemical characterization of medical devices. Over the course of his nearly 30-year academic and industry career, he has published extensively in the area of analytical chemistry with nearly 50 publications, eight of which were devoted to the chemical characterization of medical devices over the last three years. He also served as frequent scientific reviewers for over ten international journals.
He received his PhD in analytical chemistry from Purdue University, and did his postdoctoral research @ University of Minnesota.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 1: MARCH 7th, 2024

SESSION: The current state and analytical challenges with the evaluation of E&L in pharmaceutical and medical device industries

◆  The safety and analytical science expectations of E&L from the perspective of a quantitative “global” space of extractables and leachables in volatility, hydrophobicity, and molecular weight.

◆  A critical review of the current state of analytical testing strategies, including uncertainty on E&L testing.

◆  A critical overview of the major analytical challenges in solvent choice, sample treatment, mass balance, method sensitivity, response factor, accuracy of quantitation and identification, etc, with specific examples.

◆  Tips for choosing an analytical partner.

]]>
6478
Candice Johnson https://www.uventia.com/speaker/candice-johnson/ Thu, 26 Oct 2023 17:39:52 +0000 https://www.uventia.com/?post_type=speaker&p=6453
Candice Johnson

Candice Johnson, PhD

Senior Research Scientist

Instem

Candice Johnson, Ph.D. is a Senior Research Scientist at Instem. Dr. Johnson has co-authored several peer-reviewed publications describing the implementation of in silico approaches and methodologies for gaining confidence in in silico predictions. Her work expands into novel application of in silico approaches and supports the advancement of alternative methods. She is particularly interested in the application of computational tools to support toxicological evaluations; for example, in the assessment of extractables and leachables.

SPEAKED ABOUT:
4th Annual Extractables & Leachables
March 7, 2024
What is next in testing and analyzing for extractables and leachables in biopharmaceutical development and release? Recording of 2 days event sessions [18 video sessions].
Expired

DAY 1: MARCH 7th, 2024

SESSION: Approaches to the use of in silico methods in the toxicological assessment of extractables and leachables

◆  Discusses various contexts in which in silico methods are applied in E&L assessments.

◆  Defines the fitness-for-purpose of in silico models in these contexts.

◆  Demonstrates how in silico profiling could be used to support read-across assessments.

]]>
6453